Ilkowski I Partnerzy sp.p. Lekarzy

The trials here

What the 28 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis12 trials
• Myasthenia gravis8 trials
• Alzheimer disease6 trials
• Atrial fibrillation1 trial
• Obesity1 trial
• Stroke1 trial

Phase

• Phase 319 trials
• Phase 26 trials
• Phase 1/22 trials
• Phase 11 trial

Status

• Active, not recruiting10 trials
• Completed8 trials
• Recruiting7 trials
• Not yet recruiting3 trials

Lead sponsor

• TG Therapeutics, Inc.4 trials
• Eli Lilly and Company2 trials
• Immunic AG2 trials
• Novo Nordisk A/S2 trials
• UCB Biopharma SRL2 trials
• and 15 more

Running trials

• Not yet recruiting

  Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes

  NCT07896265· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

  NCT07673744· Phase 2· TG Therapeutics, Inc.· Source

• Recruiting

  A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

  NCT07647510· Phase 3· Dianthus Therapeutics· Source

• Active, not recruiting

  A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

  NCT07501702· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

  NCT07503873· Phase 2· TG Therapeutics, Inc.· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

  NCT07250750· Phase 1/2· ImmunAbs Inc.· Source

• Active, not recruiting

  Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

  NCT06847724· Phase 3· Sandoz· Source

• Active, not recruiting

  A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

  NCT06456580· Phase 3· Vor Biopharma· Source

• Active, not recruiting

  Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases

  2023-509555-13-00· Phase 1· Tg Therapeutics Inc.· Source

• Active, not recruiting

  A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.

  2022-501622-37-00· Phase 3· Celltrion Inc.· Source

• Recruiting

  Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

  NCT05877963· Phase 3· TG Therapeutics, Inc.· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

  NCT05508789· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

  NCT05201638· Phase 3· Immunic AG· Source

• Recruiting

  Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis

  NCT05054140· Phase 2· Immunic AG· Source

• Recruiting

  A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

  NCT04752774· Phase 1/2· Ipsen· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

  NCT04586023· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

  NCT04130997· Phase 3· TG Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis5 recruiting
• Myasthenia gravis4 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

  NCT06471361· Phase 3· UCB Biopharma SRL· Source

• Completed

  A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

  NCT05798520· Phase 2· Biogen· Source

• Completed

  A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

  NCT05318976· Phase 2· Inmune Bio, Inc.· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT04408755· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Completed

  Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

  NCT04225871· Phase 3· UCB Biopharma SRL· Source